NCAC - Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business Combination | Benzinga
The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc. and special purpose acquisition company Newcourt Acquisition Corp (NASDAQ: NCAC) announced that the SEC made effective a Form F-4 registration statement for a new business on November 13.
Psyence Group’s CEO, Dr Neil Maresky says receiving SEC’s effectiveness is "one step closer to a listing on a U.S. national security exchange” and enhances the company’s corporate profile while it aims to launch a Phase 2b clinical trial on nature-derived psilocybin in palliative care.
Filed by new public company Psyence Biomedical Ltd., the statement is linked to an announced business combination between Newcorp and Psyence’s wholly-owned subsidiary, Psyence Biomed ...